Skip to main content

Table 5 Percent Change in Functional Measures in Pimobendan versus Placebo Groups

From: Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy

  Post-pimobendan Post-placebo P value
LAFS 2-D4 [median % change (IQR)] 12.08 (6.25, 17.43) −5.77 (− 19.75, 3.28) 0.03
Mitral TDI S5 (mean % change ± SD) 10.76 ± 19.85 −6.42 ± 23.07 0.11
LVOT Vmax5 (mean % change ± SD) 20.08 ± 28.92 20.39 ± 31.51 0.96
RVOT Vmax5 (mean % change ± SD) 22.6 ± 23.8 19.92 ± 10.25 0.68
HR at LVOT Vmax5 (mean % change ± SD) 4.67 ± 6.7 2.8 ± 12.8 0.72
HR at RVOT Vmax5 (mean bpm ± SD) 5.1 ± 12.9 6.26 ± 9.30 0.80
  1. 4Mann-Whitney U Test
  2. 5Welch’s T Test
  3. LAFS, left atrial fractional shortening; 2-D, 2-dimensional echocardiography; SD, standard deviation; TDI, tissue Doppler imaging; LVOT Vmax, left ventricular outflow tract maximal velocity, IQR interquartile range, RVOT Vmax, right ventricular outflow tract maximal velocity